CLINICAL_TRIALS
trial_result
· 2022-04-21
Clinical Trial Update: Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma [Phase 2]
Summary
Phase 2 trial evaluating pembrolizumab in combination with ipilimumab after prior immunotherapy in melanoma, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Chicago | Conditions: Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-04-21